📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
143 announcements match the current filters (relevance ≥ 5).
Jubilant Ingrevia: India Ratings Affirms AA+/Stable Rating for Rs 23,883.8 Mn Bank Facilities
India Ratings and Research has reaffirmed Jubilant Ingrevia Limited's credit rating for its bank loan facilities at IND AA+ with a Stable outlook. The total rated bank facility amount has been marginally reduced to Rs 23,883.8 million from the previous Rs 24,200 million. Furthermore, the rating for a proposed Commercial Paper worth Rs 4,000 million has been withdrawn. This affirmation indicates that the company maintains a strong credit profile and financial stability.
Key Highlights
India Ratings affirmed 'IND AA+/Stable/IND A1+' rating for bank loan facilities.
Total bank loan facility size reduced from Rs 24,200 million to Rs 23,883.8 million.
Rating for proposed Commercial Paper of Rs 4,000 million has been withdrawn (WD).
The stable outlook suggests consistent financial performance and debt-servicing capability.
👀 What to Watch
Investors should take comfort in the affirmation of a high credit rating, which signifies low credit risk; no immediate portfolio action is required.
Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.
Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. He previously served as CEO of Ambrx Biopharma, where he drove a significant increase in company valuation leading to its acquisition. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.
Key Highlights
Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has more than 30 years of leadership experience.
Jubilant Therapeutics Inc. is in Phase I/II clinical trial in multiple tumors with JBI-802.
👀 What to Watch
Investors should monitor the progress of Jubilant Therapeutics' clinical trials and any strategic collaborations. Keep an eye on how this leadership change impacts the development of new therapies.
Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.
Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. Previously, he served as CEO of Ambrx Biopharma, leading to a significant increase in company valuation and its subsequent acquisition. He also contributed to the development of a major oncology therapy at ImClone Systems. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.
Key Highlights
Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has over 30 years of leadership experience in Biotechnology and Oncology.
Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company.
Jubilant Therapeutics Inc. is developing precision oral medicines for oncology and autoimmune diseases.
👀 What to Watch
Investors should monitor the performance of Jubilant Therapeutics under the new CEO, focusing on the progress of its clinical pipeline and strategic collaborations. Keep an eye on news related to JBI-802 and the novel brain-penetrant modulator of PRMT5.
